Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.54 |
| ▸ | FABP3 | P05413 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167244 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL3407184 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL37548 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL3409080 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL41701 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL16598280 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL42345 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL15052353 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| Ammonia Solution, Strong SCHEMBL14632885 | 0.99 | ALDH1A1 (0.61) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| Ammonia Solution, Strong SCHEMBL14632795 | 0.99 | ALDH1A1 (0.61) | ALDH1A1LMNALPAR3LPAR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| EP-4704807-A1 | INKT CELL MODULATOR LIPOSOMAL COMPOSITIONS AND METHODS OF USE | IOX Therapeutics Limited (GB) | 2026-03-11 | — | — | EP | claimed |
| US-12551436-B2 | Dosing regimens for treatment of proliferative disorders | SIGNPATH PHARMA INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-3773529-B1 | DOSING REGIMENS FOR TREATMENT OF PROLIFERATIVE DISORDERS | SIGNPATH PHARMA INC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4637983-A1 | METHOD FOR PROVIDING A LIPOSOME SOLUTION FOR FORMATION OF MICROVESICLES | DEMCON CURONIX B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| EP-3787601-B1 | LIPOSOMAL NANO FORMULATION OF COMBINATIONAL ANTIBIOTICS AND THE USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250177301-A1 | TRIPLEX NANOPARTICLES | UNM RAINFOREST INNOVATIONS | 2025-06-05 | — | — | US | claimed |
| US-20250144088-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-08 | — | — | US | claimed |
| WO-2025075976-A2 | METHYL-BRANCHED LIPOSOMES FOR SUSTAINED DRUG DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-10 | — | — | WO | claimed |
| US-8779004-B2 | Stable emulsion formulations | AMGEN, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130315983-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-11-28 | — | — | US | claimed |
| US-20130177629-A1 | LIPOSOMAL COMPOSITIONS | NUVO RESEARCH GMBH (DE) | 2013-07-11 | — | — | US | claimed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | claimed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | claimed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | claimed |
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | MIV THERAPEUTICS, INC. (CA) | 2008-07-31 | — | — | US | claimed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885LMNA 1949/4885LPAR3 169/4885 |
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | ALDH1A1 1605/4885LMNA 101/4885LPAR3 726/4885 |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885LMNA 1949/4885LPAR3 169/4885 |
| US-20080181928-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY | LIPA, SGMS2, SGMS1 | ALDH1A1 4605/4885LMNA 2993/4885LPAR3 214/4885 |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | ALDH1A1 3003/4885LMNA 3745/4885LPAR3 77/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885LMNA 640/4885LPAR3 88/4885 |
| US-12551436-B2 | Dosing regimens for treatment of proliferative disorders | CCND2, CCND1, CCNE2 | ALDH1A1 1809/4885LMNA 826/4885LPAR3 244/4885 |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | CCND1, CCND2, CCNE2 | ALDH1A1 2463/4885LMNA 1305/4885LPAR3 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.